The full content of Annals is available to subscribers

Subscribe/Learn More  >
Diagnosis and Treatment |

Treatment of Hyperthyroid Disease

Irwin Klein, MD; David V. Becker, MD; and Gerald S. Levey, MD
[+] Article, Author, and Disclosure Information

From North Shore University Hospital, Cornell University Medical College, and New York Hospital-Cornell Medical Center, New York, New York; Merck & Co., Inc., Whitehouse Station, New Jersey. Requests for Reprints: Irwin Klein, MD, Chief, Division of Endocrinology, North Shore University Hospital/Cornell University Medical College, 300 Community Drive, Manhasset, NY 11030.

Copyright ©2004 by the American College of Physicians

Ann Intern Med. 1994;121(4):281-288. doi:10.7326/0003-4819-121-4-199408150-00010
Text Size: A A A

Purpose: To evaluate treatments for hyperthyroid disease.

Data Sources: Selected studies published during the last 20 years addressing the diagnosis, causes, and treatment of hyperthyroid disease.

Study Selection: Studies were chosen based on their usefulness in addressing specific points in the treatment of hyperthyroid disease.

Data Extraction: Various treatment principles extracted from the references form the basis for the conclusions and recommendations made here.

Results: Hyperthyroid disease is a common endocrine disease. Although Graves disease is the most common cause of thyrotoxicosis, other primary and secondary causes exist. With classic signs and symptoms accompanied by confirmatory laboratory measures of thyroid hyperfunction, the diagnosis can be established firmly. Radioiodine is the preferred method to treat Graves disease; however, recent data concerning treatment with a combination of propylthiouracil and thyroxine require further evaluation to establish its efficacy. Radioiodine is also the preferred treatment for the other forms of hyperthyroid disease; however, patient-specific considerations in both may require patient-tailored therapies.

Conclusions: Hyperthyroid disease can be treated definitively for most patients. Palliative therapy with β-adrenergic blockade is useful in some patients. Further studies are needed to determine whether more recently described treatments have improved efficacy and whether therapy directed specifically at the underlying immunologic cause of Graves disease can be used successfully.





Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Submit a Comment/Letter
Submit a Comment/Letter

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.


Buy Now for $32.00

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Related Articles
Related Point of Care
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.